Press Detail





Biotest AG: Biotest achieves further milestones in its monoclonal antibody development

Biotest AG / Research Update

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Biotest achieves further milestones in its monoclonal antibody development

· Phase I clinical trial confirms good tolerability profile of BT-061. 
· Start of production for the clinical testing of BT-062.

Dreieich, 25 June 2007. The monoclonal antibody BT-061, developed by
Biotest AG, Dreieich, has demonstrated a very good tolerability profile in
a recently completed Phase I clinical study. No relevant clinical side
effects were detected in the range of doses tested. In light of existing
positive pre-clinical data, the results were in line with expectations.
They represent a key milestone in the development of the antibody for the
indications of rheumatoid arthritis and psoriasis. Biotest anticipates that
further results on the efficacy of BT-061 in these indications will be
available at the beginning of next year.

The development of Biotest's two other monoclonal antibodies is also
progressing according to plan. For BT-062, which is being developed to
treat the cancer multiple myeloma, clinical testing is set to commence at
the Dana Farber Cancer Institute in Boston and other centres in the USA in
the first half of 2008. The development and trial design has already been
agreed on by the US Food and Drug Administration (FDA). A few days ago,
manufacturing of the trial material began in line with Good Manufacturing
Practice (GMP) regulations.

With regard to BT-063, Biotest is currently developing the manufacturing
process. This monoclonal antibody specifically neutralises a cell growth
factor, which plays a major role in the formation and progression of
Systemic Lupus Erythematodes, a chronic autoimmune disease.


About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.

Biotest AG: 
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
marion_wendorff@biotest.de
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 
DGAP 25.06.2007 
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstr. 5
              63303 Dreieich Deutschland
Phone:        +49 - 6103 / 801 - 0
Fax:          +49 - 6103 / 801 - 150
E-mail:       mail@biotest.de
Internet:     www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Indices:      
Listed:       Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
              Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------